Status: Not yet recruiting
Investigating a Personalized Approach to Anti-Platelet Therapy
RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.
Participants needed: 1,760
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Ottawa Heart Institute Research CorporationUpdated: May 22, 2026Locations: 1
Eligibility criteria
Age >18 years old [+1]
Inability to take ticagrelor [+3]